Dr. Reddy's Launches First Generic Semaglutide Injection in Canada
RDY is trading near its 52-week low of $12.185 (12% above the low).
Summary
Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, marking the first generic entry into a G7 market for this blockbuster drug.
Key Events · Product Development and Regulatory · RDY
-
Generic Semaglutide Launched in Canada
Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, making it available to patients.
-
First Generic in a G7 Country
This launch marks the first time a generic Semaglutide Injection has received market authorization and launched in a G7 country (Canada).
-
Follows Health Canada Approval
The launch comes shortly after the company received Health Canada approval on April 28, 2026, for the generic version of the drug.
-
Strategic GLP-1 Expansion
The Canada launch builds on the company's recent introduction of generic Semaglutide in India and highlights its focus on expanding access to GLP-1 therapies globally.
Analysis · RDY · Life Sciences
Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, becoming the first company to introduce this product in a G7 country. This launch follows Health Canada approval and positions Dr. Reddy's to capture a significant share of the market for this high-demand diabetes and weight-loss drug, building on its recent launch in India.
At the time of this filing, RDY was trading at $13.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $12.19 to $16.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.